Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to invite grant applications to establish new and innovative epidemiology cohort studies that will prospectively follow at least 2,000 participants and are designed to study a wide range of research hypotheses related to heart, lung, blood, and/or sleep phenotypes. Through this FOA, the National Heart, Lung, and Blood Institute (NHLBI) will support activities required to establish a new cohort, including identification and recruitment of cohort participants, detailed baseline data collection on all participants, biospecimen collection and storage, study infrastructure, and data quality control and analysis.

This Funding Opportunity Announcement (FOA) seeks grant applications for a Research Coordinating Center (RCC) to support associated "Heart, Lung, and Blood Co-morbiditieS Implementation Models in People Living with HIV (HLB SIMPLe)" UG3/UH3 phased cooperative agreements that propose to optimally and sustainably address late-stage implementation research questions to address the delivery of proven-effective prevention and treatment interventions for heart, lung, blood, and sleep (HLBS) comorbid diseases and disorders in people living with HIV (PLHIV) in World Bank designated low- and middle-income countries (LMICs) and Small Island Developing States (SIDS). For the purposes of this FOA, late-stage implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions in routine clinical, public health, and community-based settings and maximize the positive impact on population health. The RCC will coordinate the collaborative efforts of the global alliance of funded UG3/UH3 phased cooperative agreements conducting late-stage implementation research within the following geographical regions: East Asia and the Pacific, Europe and Central Asia, Latin America and the Caribbean, Middle East and North Africa, South Asia, and Sub-Saharan Africa. The HLB SIMPLe RCC will coordinate activities including in-person and virtual Network Steering Committee meetings, subcommittee meetings, and working groups; promote collaboration and communication among investigators and the broader research community; coordinate network outreach activities; coordinate joint research and capacity building efforts conducted across the HLB SIMPLe alliance; and organize, implement, and manage a global implementation research data safety and monitoring board (DSMB). Also listed under UG3/UH3

 The purpose of this limited competition Funding Opportunity Announcement (FOA) is to solicit the Center for International Blood and Marrow Transplant Research (CIBMTR) a limited competition application for the continued support of the Data Resource for Analyzing Blood and Marrow Transplants program. The support for this FOA is to ensure the continued availability of the CIBMTR database as a resource to investigators, transplant physicians, and healthcare policy-makers.

This FOA invites applications to develop sensitive technologies or methods for obtaining high quality and comprehensive nucleic acids-based genomic data from limited quantities of human specimens that are easy to collect, handle, and store. Applications that address all of the steps from the collection of specimens, through storage and nucleic acids extraction, to obtaining genomic data will be considered as having highest priority to this FOA. The ease of proposed sample collection methods should be at least comparable to that of the current dried blood spot collection method. The developed technologies or methods should be applicable to clinical point-of-care testing in terms of speed and ease, and ultimately have the potential to be scalable to high throughput settings, while maintaining cost effectiveness. The genomic data obtained must be at least equivalent to that which can be obtained from fresh whole blood in terms of quality and comprehensiveness. It is expected that the research conducted under this FOA will enhance the availability of comprehensive nucleic acids-based genomic data for various clinical and research applications in need of obtaining genomic data from easy-to-collect and handle human specimens.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing research on the use of current and emerging technologies for monitoring of blood glucose levels to capture the relationship between blood glucose excursions, perception of wellbeing, and cognitive status in people with type 1 diabetes (T1D). This information will inform the design of more effective interventions that may improve patient reported outcomes (PROs), including quality of life measures, and validate glycemic measures that may serve as outcomes in clinical trials to improve glucose management in T1D.

The mission of the American Society for Hematology, the world's largest professional organization dedicated to the causes and treatment of blood disorders, is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and immunologic, hemostatic and vascular systems through the promotion of research, clinical care, education, training, and advocacy in hematology. To that end, ASH is accepting proposals from hematologists whose research would not otherwise be accomplished due to cuts in NIH funding. Established in January 2013, the long-term goal of the program is to help sustain recipients' research and contribute to their retention in hematology investigation. The Bridge Grants program will provide at least thirty one-year awards annually, in the amount of $150,000 each, to ASH members who applied for an NIH R01 grant or equivalent but were denied funding due to budget cuts. Grants will support projects in basic, translational, patient-oriented, or outcomes-based research.

This Funding Opportunity Announcement (FOA) seeks applications that propose to develop and test T4 implementation strategies to identify facilitators and overcome barriers in the adaptation, integration, scale-up, and sustainability of proven-effective interventions and guidelines for preventing and/or managing heart, lung, and blood diseases and/or sleep disorders (HLBS conditions). The proposed implementation strategies must be adaptable and responsive to community needs and contexts, and must account for cultural and organizational factors. For purposes of this FOA, T4 Implementation Research is defined as research to identify strategies to enhance sustainable uptake of proven-effective interventions into routine clinical practice.

This Funding Opportunity Announcement (FOA) seeks applications for the design and development of technologies to monitor health or deliver care in a real-time, accessible, effective, and minimally obtrusive way for older adults with a chronic heart, lung, blood, or sleep (HLBS) condition. These technologies may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems and should have the goal of fostering healthy and independent living for aging adults with HLBS conditions. The development of such technologies should incorporate specific human factors for aging adults including disabilities, mild impairments, as well as chronic HLBS conditions. Technology usability for these populations must be incorporated early in the development of the design. Usability considerations include but are not limited to patient-facing displays, hearing and visual impairments, tactile limitations, literacy, and design preferences between men and women. These improvements in technology design could yield more accurate and earlier detection of changes that may interfere with healthy and independent living for older adults.

This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. Successful applicants will provide biospecimens for whole genome sequencing or other omics assays. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public database such as dbGaP.

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies and blood biospecimens utilized as liquid biopsies. Extramural research funded under this FOA may include investigations of preanalytical variability relevant to diagnostic associated with the procurement and study of small biopsies (core biopsies, small excision samples), pleural aspirates, and blood utilized for liquid biopsies. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing research on the use of current and emerging technologies for monitoring of blood glucose levels to capture the relationship between blood glucose excursions, perception of wellbeing, and cognitive status in people with type 1 diabetes (T1D). This information will inform the design of more effective interventions that may improve patient reported outcomes (PROs), including quality of life measures, and validate glycemic measures that may serve as outcomes in clinical trials to improve glucose management in T1D.

This Funding Opportunity Announcement (FOA) is to support studies that are essential, yet also sufficient, for investigators to make definitive decisions about the designs of important clinical trials within NHLBI's mission, the prevention and treatment of heart, lung, blood, and sleep disorders. This mechanism may be used to test the feasibility of novel and efficient (pragmatic) trial designs, as well as determine the feasibility of an intervention, intervention parameters, subject availability, or other information essential to complete the design of a trial. Applications should demonstrate that the proposed pilot studies are both necessary and sufficient to permit definitive decisions about the design of the subsequent clinical trial. Applicants who propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial will not be considered appropriate for this announcement. The NHLBI anticipates that the R34 award period will yield robust investigator-initiated clinical trial grant applications for the evaluation of interventions for the treatment or prevention of heart, lung, blood, or sleep disorders.

This Funding Opportunity Announcement (FOA) invites basic research project grant (R01) applications to investigate the fundamental mechanisms underlying the pathogenesis of HIV-related heart, lung, and/or blood (HLB) diseases alone and in the context of antiretroviral therapy (ART). Investigations may be conducted on various primary cell types, biospecimens, computational models, and animal models, particularly those used for HIV research. The goal is to provide the critical basic science foundation and guide the design of new therapeutic approaches for HIV-related HLB conditions in adults and children.

This Funding Opportunity Announcement (FOA) invites basic research project grant (R21) applications to investigate the fundamental mechanisms underlying the pathogenesis of HIV-related heart, lung, and/or blood (HLB) diseases alone and in the context of antiretroviral therapy (ART). Investigations may be conducted on various primary cell types, biospecimens, computational models, and animal models, particularly those used for HIV research. The goal is to provide the critical basic science foundation and guide the design of new therapeutic approaches for HIV-related HLB conditions in adults and children.

The purpose of this Funding Opportunity Announcement (FOA) is to support research to identify and evaluate the basic underlying molecular and physiological mechanisms by which the virome may influence heart, lung, and blood (HLB) health and resilience.

This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. 

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to build in-country capacity through the creation of a trans-disciplinary investigative team to guide the conduct of late-stage translation phase 4 research (T4TR) in low income countries (as defined by The World Bank) through skills development programming, needs assessment, and capacity building. Studies will be required to address chronic non-communicable heart, lung, blood and sleep diseases and disorders in low income countries.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to build in-country capacity through the creation of a trans-disciplinary investigative team to guide the conduct of late-stage translation phase 4 research (T4TR) in low income countries (as defined by The World Bank) through skills development programming, needs assessment, and capacity building. Studies will be required to address chronic non-communicable heart, lung, blood and sleep diseases and disorders in low income countries.

The purpose of this Funding Opportunity Announcement (FOA) is to support research to identify and evaluate the basic underlying molecular and physiological mechanisms by which the virome may influence heart, lung, and blood (HLB) health and resilience.    

This Funding Opportunity Announcement (FOA) seeks late-stage T4 Translation research (T4TR) and implementation studies that will lead to generalizable new knowledge to accelerate the adoption/adaptation, and sustained, high-fidelity use of proven-effective interventions for the prevention, treatment, and control of heart, lung, blood, and sleep disorders or diseases (HLBS conditions). It calls for multi-level strategies for delivery of proven-effective interventions to promote the prevention and management of HLBS conditions. The system-level change(s) being evaluated are to be designed, and findings reported so that others would have a contextually-informed understanding of workflow, workforce, and trade-off considerations. These considerations should reflect cultural and organizational contextual factors and values as they inform feasibility and flexibility of adopting, adaptable and sustainable, proven-effective interventions to address HLBS conditions.

The purpose of this funding opportunity announcement (FOA) is to support functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their components in the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translational approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiology, pulmonology, hematology, sleep science, circadian biology, immunology, '-omic' sciences, microbiology, microbial ecology, biotechnology, and bioinformatics.